Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Neoplasms, Human”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT06597175
What this trial is testing

Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy

Who this might be right for
Breast CancerBreast TumorMammary Carcinoma, Human
Olive Healthcare 300
Large-scale testing (Phase 3)Looking for participantsNCT05827081
What this trial is testing

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 1,400
Large-scale testing (Phase 3)Looking for participantsNCT05901428
What this trial is testing

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Fudan University 1,736
Early research (Phase 1)Looking for participantsNCT07334119
What this trial is testing

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-Expressing Solid Tumors
Myeloid Therapeutics 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04906395
What this trial is testing

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Who this might be right for
Breast Cancer
Tolmar Inc. 250
Early research (Phase 1)Study completedNCT03595059
What this trial is testing

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Who this might be right for
Advanced Solid Tumors
AbbVie 168
Large-scale testing (Phase 3)Study completedNCT04629846
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 517
Testing effectiveness (Phase 2)Active Not RecruitingNCT04172259
What this trial is testing

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Who this might be right for
Breast CancerNeoadjuvant Chemotherapy
Sun Yat-sen University 156
Early research (Phase 1)UnknownNCT05673694
What this trial is testing

To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Changchun GeneScience Pharmaceutical Co., Ltd. 70
Large-scale testing (Phase 3)Looking for participantsNCT05760612
What this trial is testing

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Who this might be right for
Early-stage Breast CancerHER2-positive Breast CancerAdjuvant Treatment After Trastuzumab+2 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Not applicableNot Yet RecruitingNCT06950671
What this trial is testing

Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study

Who this might be right for
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage III+1 more
Rahma Esam Salama Esawi 1
Early research (Phase 1)Study completedNCT00426556
What this trial is testing

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 88
Early research (Phase 1)Study completedNCT04176757
What this trial is testing

ZN-c5 in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Zeno Alpha Inc. 35
Early research (Phase 1)Study completedNCT00096057
What this trial is testing

Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 24
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Active Not RecruitingNCT05558722
What this trial is testing

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer Stage II
Xijing Hospital 31
Early research (Phase 1)Study completedNCT03471663
What this trial is testing

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 200
Early research (Phase 1)Looking for participantsNCT05187832
What this trial is testing

AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC 61
Early research (Phase 1)Active Not RecruitingNCT05654532
What this trial is testing

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 100
Large-scale testing (Phase 3)Study completedNCT04109066
What this trial is testing

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 521
Next Page